ANI Pharmaceuticals (BSFA) Stock Statistics & Valuation Metrics

ANI Pharmaceuticals has a market cap or net worth of CHF1.50B. The enterprise value is CHF1.94K.

ANI Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

ANI Pharmaceuticals’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 5.63%.

The current PE Ratio of ANI Pharmaceuticals is 19.7. ANI Pharmaceuticals’s PEG ratio is -0.05.

In the last 12 months, ANI Pharmaceuticals had revenue of 883.37M and earned 78.34M in profits. Earnings per share was 3.50.

In the last 12 months, operating cash flow was 208.61M and capital expenditures -48.26M, giving a free cash flow of 160.35M billion.

ANI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

ANI Pharmaceuticals upcoming earnings date is Aug 7, 2026, Before Open (Confirmed).

ANI Pharmaceuticals as a current ratio of 2.71, with Debt / Equity ratio of 58.29%

In the past 12 months, ANI Pharmaceuticals has paid 17.45M in taxes.

ANI Pharmaceuticals EV to EBITDA ratio is 7.83, with an EV/FCF ratio of 10.75.

ANI Pharmaceuticals has CHF311.18M in cash and marketable securities with CHF327.76M in debt, giving a net cash position of -CHF16.59M billion.

Gross margin is 65.94%, with operating margin of 9.20%, and net profit margin of 8.87%.

The average price target for ANI Pharmaceuticals is CHF89.22, which is 11.43% higher than the current price. The consensus rating is Moderate Buy